Chlorproguanil-Dapsone with Artesunate for Malaria Treatment
Author Information
Author(s): Wootton Daniel G., Opara Hyginus, Biagini Giancarlo A., Kanjala Maxwell K., Duparc Stephan, Kirby Paula L., Woessner Mary, Neate Colin, Nyirenda Maggie, Blencowe Hannah, Dube-Mbeye Queen, Kanyok Thomas, Ward Stephen, Molyneux Malcolm, Dunyo Sam, Winstanley Peter A.
Primary Institution: University of Liverpool
Hypothesis
What is the appropriate dose of artesunate to use in combination with chlorproguanil-dapsone for treating uncomplicated falciparum malaria?
Conclusion
The study found that adding artesunate to chlorproguanil-dapsone significantly improved the time to reduce malaria parasites compared to chlorproguanil-dapsone alone.
Supporting Evidence
- Adding artesunate reduced the mean time to achieve a 90% reduction in parasitemia compared to chlorproguanil-dapsone alone.
- Children showed a significant reduction in parasite viability with higher doses of artesunate.
- Adverse events were similar across treatment groups, indicating no significant safety concerns with the combination therapy.
Takeaway
This study tested different doses of a medicine to see which one works best for treating malaria. They found that a higher dose helped people get better faster.
Methodology
An open-label clinical trial comparing chlorproguanil-dapsone alone or with artesunate at three different doses in adults and children with uncomplicated malaria.
Potential Biases
Potential bias due to the open-label design and differences in adverse event reporting between study centers.
Limitations
The study was not powered to detect differences in clinical endpoints and had stringent inclusion criteria that may limit generalizability.
Participant Demographics
116 adults (median age 27 years) and 107 children (median age 38 months) with uncomplicated malaria.
Statistical Information
P-Value
0.002
Confidence Interval
−14.1, −3.2
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website